FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/04/108942 [Registered on: 21/04/2026] Trial Registered Prospectively
Last Modified On: 17/04/2026
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Mobile App based intervention on Metabolic Syndrome and Treatment Adherence]  
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Use of a Mobile Phone App to Improve Metabolic Health and Treatment Adherence in Adult Cancer Patients 
Scientific Title of Study   A Randomized Controlled Trial to evaluate the Effectiveness of Mobile App (CANMET)Based Interventions on Metabolic Syndrome and Treatment Adherence among Adult Oncology Patients Receiving Systemic Anticancer Treatment in IRCH, AIIMS New Delhi. 
Trial Acronym  MS APP 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Jeena John 
Designation  M.Sc (Nursing) (oncology Nursing) 
Affiliation  AIIMS, New Delhi 
Address  College of Nursing, Porta Cabin, Near Old OT Block, AIIMS, New Delhi.

New Delhi
DELHI
110029
India 
Phone  9643355584  
Fax    
Email  lizjohnrose@gmail.com  
 
Details of Contact Person
Scientific Query  
Name  Dr Latha Venkatesan 
Designation  Professor cum Principal 
Affiliation  AIIMS, New Delhi 
Address  Room No.1, Ground floor, College of Nursing, Near Old OT block, AIIMS, New Delhi.

New Delhi
DELHI
110029
India 
Phone  9310502069  
Fax    
Email  latha6901@yahoo.com  
 
Details of Contact Person
Public Query  
Name  Dr Latha Venkatesan 
Designation  Professor cum Principal 
Affiliation  AIIMS, New Delhi 
Address  Room No.1, Ground floor, College of Nursing, Near Old OT block, AIIMS, New Delhi.

New Delhi
DELHI
110029
India 
Phone  9310502069  
Fax    
Email  latha6901@yahoo.com  
 
Source of Monetary or Material Support  
NIL 
 
Primary Sponsor  
Name  Jeena John 
Address  Porta Cabin, College of Nursing Near Old OT Block, AIIMS, New Delhi. India 110074 
Type of Sponsor  Other [Academic purpose] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DrLatha Venkatesan  AIIMS, New Delhi  MRO Ward, Daycare, MO Ward Dr B.R.A. IRCH, AIIMS, New Delhi 110074
South
DELHI 		 9310502069

latha6901@yahoo.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
INSTITUTE ETHICS COMMITTEE FOR POSTGRADUATE RESEARCH,ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI 110029  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C00-D49||Neoplasms, (2) ICD-10 Condition: E70-E88||Metabolic disorders,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  CANMET mobile app based intervention  The interventions will be delivered via the CANMET Mobile App, a digital health platform designed to support for MetS management and treatment adherence on the following components • Lifestyle modification • Dietary counselling • Physical activity guidance • Sleep hygiene • Stress management • Pharmacological support and monitoring schedule Participants of the mobile application group will get a description about the features of the app and how to install and use it. The intervention and follow-up period will be 3 months.  
Comparator Agent  Standard care  Standard nursing care 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  75.00 Year(s)
Gender  Both 
Details  1.Adult aged more than 18 years with a confirmed diagnosis of Ca Breast, Ca colon, GCT, Lymphoma, ca ovary
2. Currently receiving /initiated active adjuvant chemotherapy within the past 1 month
3. Individuals who meet the NCEP ATP III criteria
4. Individuals who have access to a smart phone
 
 
ExclusionCriteria 
Details  1.Patient’s receiving palliative chemotherapy or having confirmed metastatic disease.
2.participating in another medical research or lifestyle intervention that may interfere with outcome.
3.Patients with cognitive or sensory impairments
4.Patients who are unable to read or understand the app content
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Metabolic Syndrome components, Treatment Adherence  6 weeks 
 
Secondary Outcome  
Outcome  TimePoints 
feasibility and acceptability of CANMET App   6 weeks 
association between sociodemographic variables, and metabolic syndrome components, treatment adherence, in the experimental group before and after receiving CANMET mobile app- based interventions  6 weeks 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   01/08/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="3"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - All of the individual participant data collected during the trial, after de-identification.

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Informed Consent Form

  3. Who will be able to view these files?
    Response - Researchers who provide a methodologically sound proposal.

  4. For what types of analyses will this data be available?
    Response - For individual participant data meta-analysis.

  5. By what mechanism will data be made available?
    Response - Proposals should be directed to [lizjohnrose@gmail.com].

  6. For how long will this data be available start date provided 30-11-2027 and end date provided 19-07-2032?
    Response - Beginning 9 months and ending 36 months following article publication.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - Nil
Brief Summary   This study is conducted for early identification of metabolic disorders in cancer patients who are in the initial period of chemotherapy, as metabolic syndrome will interfere with their prognosis and survival. If metabolic syndromes are identified during their initial treatment period of chemotherapy, with proper interventions and adequate treatment adherence measures, we can improve their long-term health and quality of life of cancer survivors. There are so many studies on cancer survivors, but very few studies on the active treatment period of chemotherapy and metabolic syndrome interventions. The CANMET App is a mobile app-based intervention on metabolic syndrome and treatment adherence , which helps the adult oncology patients to an improved, sustained period of survivorship. An RCT is the most rigorous method to determine if the CANMET APP is truly effective over standard care, justifying its widespread adoption and integration into the national care protocol. 
Close